Marilyn M. Day
Affiliations: | 2016-2018 | National Institutes of Health, Bethesda, MD |
Google:
"Marilyn Day"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Free RB, Cuoco CA, Xie B, et al. (2021) Pharmacological characterization of the imipridone anti-cancer drug ONC201 reveals a negative allosteric mechanism of action at the D dopamine receptor. Molecular Pharmacology |
| Prabhu V, Cuoco C, Jung J, et al. (2020) DDRE-33. MOLECULAR DIFFERENTIATION OF IMIPRIDONES ONC201 AND ONC206 Neuro-Oncology. 22: ii68-ii68 |
| Keck TM, Free RB, Day MM, et al. (2019) Dopamine D4 Receptor-Selective Compounds Reveal Structure-Activity Relationships that Engender Agonist Efficacy. Journal of Medicinal Chemistry |
| Benjamin Free R, Cuoco C, Prabhu V, et al. (2019) EXTH-33. RECEPTOR PHARMACOLOGY OF ONC201: THE FIRST BITOPIC DRD2 ANTAGONIST FOR CLINICAL NEURO-ONCOLOGY Neuro-Oncology. 21: vi89-vi89 |
| Prabhu V, Cuoco C, Jung J, et al. (2019) DDIS-20. IMIPRIDONE STRUCTURE ACTIVITY RELATIONSHIP UNCOVERS ONC206 AS THE NEXT BITOPIC DRD2 ANTAGONIST FOR ONCOLOGY WITH DIFFERENTIATED RECEPTOR PHARMACOLOGY Neuro-Oncology. 21: vi67-vi67 |
| Cuoco CA, Free RB, Willette BK, et al. (2018) Characterization of the novel anti-cancer therapeutic ONC201 and related analogs as non-competitive antagonists of the D2 dopamine receptor The Faseb Journal. 32 |